Benzinga | Jul 14, 2021 04:05PM EDT

Codexis Announces Completion of CodeEvolver License Technology Transfer with Global Pharmaceutical Leader

Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver(r) platform technology transfer with Novartis Pharma AG ("Novartis") today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver(r) to develop novel performance enzymes for use in the manufacture of pharmaceutical products.



"We are pleased to have completed the CodeEvolver(r) installation for Novartis, enabling our long-time customer to leverage Codexis' proprietary enzyme engineering technology," said Stefan Lutz, Senior Vice President of Research of Codexis. "Compared to using traditional, non-enzymatic chemistry, CodeEvolver(r)-improved enzymes and processes can reduce capital requirements, and enable higher yielding processes, with reduced energy usage and lower waste generation. This is our third licensing collaboration for a customer to bring CodeEvolver(r) technology in-house, but the first one we have had to implement virtually; I'm extremely proud of how our teams collaborated to ensure a successful and efficient technology transfer, despite the challenges of the pandemic."